ClinicalTrials.gg

Program

Nalbuphine

Also written as “NAL ER”, “nalbuphine HCl ER” and “Nalbuphine Hydrochloride Injection”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Prurigo · Pruritus · Chronic Cough · Opioid-Related Disorders, led by 4 companies.

Furthest: phase 4, since May 17, 201420 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Trevi Therapeutics173 open or runningphase 3since May 17, 2014May 17, 2014Aug 2027phase 3 · NCT07868419
Lumosa Therapeutics10 open or runningphase 1since May 13, 2015May 13, 2015none ahead
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical10 open or runningphase 3since Apr 1, 2025Apr 1, 2025none ahead
Yung Shin Pharm. Ind.10 open or runningphase 4since Jan 27, 2019Jan 27, 2019none ahead

Also a collaborator on its studies: parexel and davita-clinical-research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since May 17, 2014.

  1. Feb 13, 2015Phase 1 study in Uremic PruritusTrevi Therapeutics · NCT02373215 · 22 enrolled
  2. May 13, 2015Lumosa Therapeutics's first study: phase 1 study in PainNew to Lumosa TherapeuticsLumosa Therapeutics · NCT02446301 · 12 enrolled · Taiwan
  3. Mar 22, 2018Phase 3 study in Prurigo NodularisTrevi Therapeutics · NCT03497975 · 353 enrolled · United States, Austria, France and more
  4. Jan 27, 2019Yung Shin Pharm. Ind.'s first study: phase 4 study in Pain, PostoperativeNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT03826316 · 14 enrolled · Taiwan
  5. May 30, 20192 phase 1 studiesTrevi Therapeutics · NCT04020016, NCT04018664
  6. Jul 11, 2019Phase 2 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT04030026 · 42 enrolled · United Kingdom
  7. Jul 7, 20232 phase 2 studiesTrevi Therapeutics · NCT05964335, NCT05962151
  8. Apr 1, 2025Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical's first study: phase 3 study in Postoperative AnalgesiaNew to Yangtze River Pharmaceutical Group Jiangsu Zilong PharmaceuticalYangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical · NCT06949852 · 289 enrolled · China
  9. May 29, 2025Phase 1 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07036029 · 9 enrolled · United States, United Kingdom
  10. Jun 3, 2025Phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07015398 · 132 enrolled · United States
  11. Mar 17, 2026Phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07487740 · 60 enrolled · United States
  12. Jun 22, 2026Phase 2 study in Chronic CoughTrevi Therapeutics · NCT07671924 · 100 planned · Canada, United Kingdom
  13. Jun 22, 2026Phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07671911 · 306 planned · United States
  14. Oct 5, 2026Phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07868419 · 201 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07868419
  2. Sep 2027Primary completion: phase 2 study in Chronic CoughTrevi Therapeutics · NCT07671924
  3. Jun 2028Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07671911

TargetBeta

“Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
cebranopadolruleTris Pharmaphase 318

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07868419Idiopathic Pulmonary Fibrosis · United States3RecruitingTrevi TherapeuticsAug 2027201
NCT07671924Chronic Cough · Canada, United Kingdom2RecruitingTrevi TherapeuticsSep 2027100
NCT07671911Idiopathic Pulmonary Fibrosis · United States3RecruitingTrevi TherapeuticsJun 2028306
NCT07487740Healthy Participants · United States1CompletedTrevi TherapeuticsMay 11, 202660
NCT07015398Healthy Participants · United States1CompletedTrevi TherapeuticsSep 12, 2025132
NCT07036029Idiopathic Pulmonary Fibrosis · United States, United Kingdom1CompletedTrevi TherapeuticsJun 30, 20269
NCT06949852Postoperative Analgesia · China3CompletedYangtze River Pharmaceutical Group Jiangsu Zilong PharmaceuticalJul 8, 2025289
NCT05964335Idiopathic Pulmonary Fibrosis · Australia, Canada, Chile and more2CompletedTrevi TherapeuticsApr 24, 2025165
NCT05962151Chronic Cough · Canada, United Kingdom2CompletedTrevi TherapeuticsJan 6, 202566
NCT04030026Idiopathic Pulmonary Fibrosis · United Kingdom2CompletedTrevi TherapeuticsMay 27, 202242
NCT04020016Hepatic Impairment · United States1CompletedTrevi TherapeuticsFeb 5, 202028
NCT04018664Opioid-Related Disorders · Canada1CompletedTrevi TherapeuticsDec 3, 201856
NCT03826316Pain, Postoperative · Taiwan4CompletedYung Shin Pharm. Ind.Nov 22, 201814
NCT03497975Prurigo Nodularis · United States, Austria, France and more3CompletedTrevi TherapeuticsMay 10, 2022353
NCT02446301Pain · Taiwan1CompletedLumosa TherapeuticsApr 201512
NCT02373215Uremic Pruritus1CompletedTrevi TherapeuticsNov 201322
NCT02174432Prurigo · Germany3CompletedTrevi TherapeuticsSep 3, 201736
NCT02174419Prurigo · United States, Germany, Poland3CompletedTrevi TherapeuticsAug 201662
NCT02143973Pruritus · United States3CompletedTrevi TherapeuticsJan 2016167
NCT02143648Pruritus · United States, Poland, Romania3CompletedTrevi TherapeuticsJul 2015373

How it is read

Names in the registry

  • “NAL ER”, 11 entries
  • “nalbuphine HCl ER”, 2 entries
  • “Nalbuphine Hydrochloride Injection”, 1 entry
  • “Nalbuphine ER”, 1 entry
  • “Nalbuphine ER Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.